Literature DB >> 2702924

Assessment of the abuse potential of acetorphan, an enkephalinase inhibitor.

J S Knisely1, P M Beardsley, M D Aceto, R L Balster, L S Harris.   

Abstract

The discriminative stimulus properties, reinforcing effects and physical dependence potential of acetorphan, a parenterally-active enkephalinase (E.C. 3.4.21.11) inhibitor, were assessed in the present studies. Rats trained to discriminate 2 mg/kg morphine from saline did not generalize to acetorphan at any dose tested (5-50 mg/kg). Acetorphan also had minimal reinforcing effects in rhesus monkeys. When acetorphan was substituted for cocaine, one dose (300 micrograms/kg per inj.) maintained responding somewhat above the range of vehicle values in only two of the four monkeys tested. In physical dependence studies, acetorphan also failed to produce opioid-like effects. In morphine-dependent monkeys and rats, acetorphan failed to suppress withdrawal. Additionally, there were no overt withdrawal signs observed following the termination of chronic acetorphan infusion in the rat. Together, these results indicate that acetorphan appears to have minimal abuse potential.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2702924     DOI: 10.1016/0376-8716(89)90020-3

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  3 in total

1.  Effects of acetorphan, an enkephalinase inhibitor, on experimental and acute diarrhoea.

Authors:  P Baumer; E Danquechin Dorval; J Bertrand; J M Vetel; J C Schwartz; J M Lecomte
Journal:  Gut       Date:  1992-06       Impact factor: 23.059

2.  A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril.

Authors:  Marion Eberlin; Tobias Mück; Martin C Michel
Journal:  Front Pharmacol       Date:  2012-05-30       Impact factor: 5.810

3.  Evaluating the cost utility of racecadotril for the treatment of acute watery diarrhea in children: the RAWD model.

Authors:  Tamlyn Anne Rautenberg; Ute Zerwes; Douglas Foerster; Rick Aultman
Journal:  Clinicoecon Outcomes Res       Date:  2012-04-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.